The Technical Analyst
Evolent Health Inc [EVH]
Exchange: NYSE Sector: Healthcare Industry: Health Information Services
Evolent Health Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.23% $27.27
America/New_York / 8 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 147.78 mill |
| EPS: | -1.280 |
| P/E: | -21.30 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 115.43 mill |
| Avg Daily Volume: | 0.944 mill |
| RATING 2024-05-08 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -21.30 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -7.86x |
| Company: PE -21.30 | industry: PE 2.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-17.04 (-162.50%) $-44.31 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 26.35 - 28.19 ( +/- 3.37%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-07-01 | Tutewohl Steve | Buy | 9 000 | Class A Common Stock |
| 2024-03-01 | Glass Russell Monroe | Buy | 1 163 | Class A Common Stock |
| 2024-03-01 | Shams Aammaad | Buy | 7 491 | Class A Common Stock |
| 2024-03-01 | Shams Aammaad | Sell | 2 569 | Class A Common Stock |
| 2024-03-01 | Rafferty Emily Ann | Buy | 10 911 | Class A Common Stock |
| INSIDER POWER |
|---|
| -11.91 |
| Last 99 transactions |
| Buy: 2 025 507 | Sell: 2 754 196 |
Forecast:
16:00 - $27.27
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $27.27
Forecast 2: 16:00 - $27.27
Forecast 3: 16:00 - $27.27
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $27.27 (-1.23% ) |
| Volume | 0.912 mill |
| Avg. Vol. | 0.944 mill |
| % of Avg. Vol | 96.56 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EVH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EVH
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
Latest Press Releases
2024-04-18 16:30:00 - Press Release
Evolent To Release First Quarter 2024 Financial Results On Thursday, May 9, 2024
Company to participate in upcoming conferences washington , april 18, 2024 /prnewswire/ -- evolent health, inc. (nyse: evh), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial results on thursday, may 9, 2024, after market close, with a conference call to follow at 5 p.m. et. shareholders and interested participants may listen to a live broadcast of the conference found on evolent's investor relations website, https://ir.evolenthealth.com.
2024-02-22 16:10:00 - Press Release
Evolent Announces Fourth Quarter And Full Year 2023 Results
Washington , feb. 22, 2024 /prnewswire/ -- evolent health, inc. (nyse: evh), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months and year ended december 31, 2023. seth blackley, chief executive officer, and co-founder of evolent stated, "we ended 2023 on a strong note, achieving all of our financial objectives for the year.
2024-02-14 16:10:00 - Press Release
Evolent Adds Russell Glass, Headspace Ceo, To Board Of Directors
Washington , feb. 14, 2024 /prnewswire/ -- evolent health, inc. (nyse: evh), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today appointed russell glass to its board of directors. glass has almost 25 years of experience as a successful technology and health care executive who currently serves as chief executive officer of headspace , a pioneering company focused on digitally enabled mental health support for employers, health plans and consumers.
2024-01-25 07:00:00 - Press Release
Evolent To Release Fourth Quarter 2023 Financial Results On Thursday, February 22, 2024
Company to participate in upcoming investor conferences washington , jan. 25, 2024 /prnewswire/ -- evolent health, inc. (nyse: evh), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its fourth quarter 2023 financial results on thursday, feb. 22, 2024, after market close, with a conference call to follow at 5 p.m. et. shareholders and interested participants may listen to a live broadcast of the conference found on evolent's investor relations website, https://ir.evolenthealth.com.
2023-12-05 22:59:00 - Press Release
Evolent Health, Inc. Announces Pricing Of $350.0 Million Of Convertible Senior Notes Due 2029 To Pay Down Senior Term Loan
Washington , dec. 5, 2023 /prnewswire/ -- evolent health, inc. (nyse: evh), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable ("evolent"), today announced the pricing of $350.0 million aggregate principal amount of 3.50% convertible senior notes due 2029. the notes are being offered only to persons reasonably believed to be qualified institutional buyers pursuant to rule 144a under the securities act of 1933, as amended (the "securities act").
Latest News
2024-03-14 10:56:07 - Zacks Investment Research
Does Evolent Health (EVH) Have the Potential to Rally 34.46% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-02-27 10:56:06 - Zacks Investment Research
Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should Know
The consensus price target hints at a 35.7% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-02-22 22:34:06 - Seeking Alpha
Evolent Health, Inc. (EVH) Q4 2023 Earnings Call Transcript
2024-01-05 08:16:11 - Zacks Investment Research
New Strong Buy Stocks for January 5th
ORGO, CALM, W, NET and EVH have been added to the Zacks Rank #1 (Strong Buy) List on January 5, 2024.
2023-11-04 03:13:03 - Seeking Alpha
Evolent Health, Inc. (EVH) Q3 2023 Earnings Call Transcript
Evolent Health, Inc. (NYSE:EVH ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer, Co-Founder & Board Member John Johnson - Chief Financial Officer Conference Call Participants Ryan Daniels - William Blair Kevin Caliendo - UBS Unknown speaker - Guggenheim Partners Charles Rhyee - TD Cowen Jeff Garro - Stephens Inc Richard Close - Canaccord Genuity David Larsen - BTIG Sean Dodge - RBC Capital Markets Jessica Tassan - Piper Sandler Operator Welcome to the Evolent Earnings Conference Call for the quarter ended September 30th, 2023. As a reminder, this conference call is being recorded.
2023-11-02 20:17:23 - Zacks Investment Research
Evolent Health (EVH) Surpasses Q3 Earnings and Revenue Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.59 per share a year ago.
2023-10-10 17:30:00 - PRNewsWire
Evolent to release third quarter financial results on Thursday, Nov. 2, 2023, and participate in upcoming investor conferences
WASHINGTON , Oct. 10, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2023 financial results on Thursday, Nov. 2, 2023, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, ir.evolenthealth.com.
2023-10-05 13:32:37 - Zacks Investment Research
Evolent Health (EVH) Moves to Buy: Rationale Behind the Upgrade
Evolent Health (EVH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-10-04 15:16:31 - Seeking Alpha
A First Evaluation On Evolent Health
Evolent Health, Inc., is a mid-cap solutions provider in the healthcare space that made a major acquisition late last year. The stock is down some 30% from recent highs despite impressive sales growth and solid analyst firm support. Earnings will decline in FY2023 as the company integrates its new operations before rebounding significantly in FY2024.
2023-08-08 17:00:00 - PRNewsWire
Evolent Health to Participate in Upcoming Conferences
WASHINGTON , Aug. 8, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced that Chief Executive Officer Seth Blackley, Chief Financial Officer John Johnson and Vice President, Investor Relations Seth Frank will participate in upcoming investor conferences, including meetings with institutional investors and presentations. A live audio-only webcast and replay for these events will be available, if applicable, on the Investor Relations section of Evolent's website at http://ir.evolenthealth.com.